Drugs / CAL/BDP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07357831 Comparator | Dec 2025 → Oct 2026 expected | psoriasis | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Active not recruiting | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAL/BDP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07357831 ↗ |